EvoKe-HD: Evidence for Potassium Restriction in Hemodialysis

Sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06120608
Collaborator
Canadian Institutes of Health Research (CIHR) (Other)
60
1
2
35.9
1.7

Study Details

Study Description

Brief Summary

EvoKe-HD is a pilot randomized controlled trial to assess the feasibility and potential for efficacy of a novel dietary approach to hyperkalemia. Contrary to the traditional recommendations limiting the intake of high-potassium whole foods, such as fruits and vegetables, the investigators propose to switch the focus to foods containing potassium that is readily absorbed by the body (high bioavailability), such as potassium from additives, processed meats, milk, fruit juices and sugary drinks.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Novel dietary approach focused on restricting the intake of highly bioavailable potassium
  • Behavioral: Traditional approach
N/A

Detailed Description

Sixty adults receiving hemodialysis treatments with blood potassium levels ≥ 5.2 mmol/L on two occasions or more in the past three months will be randomly assigned to either the novel dietary counselling or the traditional approach. Both groups will meet with the renal dietician again once a month for 20 to 30 minutes, but the content of the recommendations will be different. The intervention and follow-up period will last six months. The investigators will record pre-dialysis potassium, bicarbonate, phosphorus, calcium and parathormone levels, blood pressure, volume status, hospitalizations, medication, and dialysis prescription changes monthly and assess nutritional status and satisfaction with food at the beginning and at the end of the study.

The study will be successful if 30% or more of the eligible patients agree to participate and complete the 6-month assessment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Treatment
Official Title:
Evidence for Potassium Restriction in Hemodialysis
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Dec 30, 2026
Anticipated Study Completion Date :
Dec 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Restriction high bioavailability potassium sources

Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.

Behavioral: Novel dietary approach focused on restricting the intake of highly bioavailable potassium
Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.

Active Comparator: Control

Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.

Behavioral: Traditional approach
Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.

Outcome Measures

Primary Outcome Measures

  1. Percentage of prevalent dialysis patients recruited and retained for 6 months [6 months]

    Primary feasibility outcome

  2. Change in average mid-week predialysis potassium level during the study period [6 months]

Secondary Outcome Measures

  1. Ratio of the number of randomized participants over the number of screened participants randomized [6 months]

    Secondary feasibility outcome

  2. Number of participants recruited 12 months into the trial [6 months]

    Secondary feasibility outcome

  3. Percentage of randomized participants who report having understood the dietary recommendations well or very well using a 1-7 Likert scale with anchors [6 months]

    Secondary feasibility outcome

  4. Percentage of randomized participants who judge the intervention to be acceptable using a 1-7 Likert scale with anchors [6 months]

    Secondary feasibility outcome

  5. Average monthly midweek pre-dialysis serum potassium level (mmol/L) [6 months]

  6. Peak serum potassium over the study period [6 months]

  7. Number of hyperkalemia (≥5.6 mmol/L) and severe hyperkalemia (>6 mmol/L) events [6 months]

  8. Number of dialysis sessions with dialysate concentration < 2mmol/L [6 months]

  9. Number of patients for whom the potassium dialysate concentration was raised or lowered (by ≥0.5mmol/L) [6 months]

  10. Total dose of potassium binders (g) over the study period [6 months]

  11. Number of participants taking potassium binders at 6 months [6 months]

  12. Healthy diet index 2020 [6 months]

    Include 13 components that reflect the key recommendations in the Dietary Guidelines for Americans, 2020-2025. The maximum score is 100.

  13. Mediterranean diet score [6 months]

    0 to 100 score; higher score represents a better adherence to the Mediterranean diet

  14. Mediterranean-diet scale [6 months]

    Score from 0 (minimal adherence to the traditional Mediterranean diet) to 9 (maximal adherence)

  15. Number of servings/day of high potassium bioavailability items (meat, dairy, juices, potatoes) [6 months]

  16. Number of servings/day of moderate to high total potassium food items [6 months]

  17. Ratio of plant to animal protein intake (g/g) [6 months]

  18. Subjective global assessment [6 months]

    Standardized subjective assessment of nutritional status performed by a dietitian. Final rating is either Well-nourished, Mildly/moderately malnourished or Severely malnourished with or without cachexia and/or sarcopenia.

  19. Albumin levels (g/L) [6 months]

  20. Pre-albumin levels (g/L) [6 months]

  21. Normalized protein nitrogen appearance (g/kg/day) [6 months]

    calculated from urea reduction ratio

  22. Body mass index (kg/m2) [6 months]

  23. Change in weight (kg) [6 months]

  24. Satisfaction with food-related life [6 months]

    5-item scale, total score range 0 to 100, higher score represents higher satisfaction with food

  25. Self-perceived impact on diet [6 months]

    "I changed my diet in the past 3 months based on the advice I received from the renal dietitian" (1-7 Likert scale with anchors)

  26. Self-perceived compliance with the dietary recommendations [6 months]

    "I am following the diet recommended by the renal dietitian" (1-7 Likert scale with anchors)

  27. Average monthly midweek pre-dialysis serum phosphate level (mmol/L) [6 months]

  28. Average monthly midweek pre-dialysis serum calcium level (mmol/L) [6 months]

  29. Pre-dialysis serum parathyroid hormone level (pmol/L) [6 months]

  30. Monthly average serum bicarbonate levels (mmol/L) [6 months]

  31. 1-week average inter-dialytic weight gain (kg/day) [6 months]

  32. 1-week average pre dialysis blood pressure (mmHg) [6 months]

  33. 1-week average post dialysis blood pressure (mmHg) [6 months]

Other Outcome Measures

  1. Major cardiovascular events [6 months]

    Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death

  2. Standardised Outcomes in NephroloGy fatigue measure [6 months]

    3 questions answered on a 4-points Likert scale. The results of each question (rated 0 to 3) is summed up to obtain to total score (range 0 to 9)

  3. All-cause mortality [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥18 years or older

  • Receiving hemodialysis 3 times/week for ≥ 3 months

  • Has at least two pre-dialysis serum potassium levels ≥5.2 mmol/L on any analysis in the past 3 months

  • Can speak and understand French or English

  • Has not missed more than 1 dialysis session in the previous 3 months.

  • Is capable of providing informed consent.

Exclusion Criteria:
  • Is not expected to survive beyond 6 months

  • Does not control their dietary intake (e.g., residents of high-dependency nursing homes)

  • Significant cognitive impairment precluding understanding of the dietary recommendations.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CIUSSS du Nord-de-l'Île-de-Montréal Montréal Quebec Canada H4J 1C5

Sponsors and Collaborators

  • Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
  • Canadian Institutes of Health Research (CIHR)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amélie Bernier-Jean, Clinical Associate Professor, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
ClinicalTrials.gov Identifier:
NCT06120608
Other Study ID Numbers:
  • pending
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Amélie Bernier-Jean, Clinical Associate Professor, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023